ResMed has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average adjusted operating margin of 30.8%. Analyzing the ...

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...

ResMed makes continuous positive airway pressure machines (CPAP), which offer a non-invasive treatment option for sleep apnea characterized by brief interruptions of breathing during sleep.

StockNews.com upgraded shares of ResMed (NYSE:RMD – Free Report) from a hold rating to a buy rating in a report released on Saturday. Several other research analysts have also issued reports on RMD.

The Luna TravelPAP is React's newest portable CPAP machine, and it doesn't look like a CPAP at all. In fact, if you were none ...

Learn More ResMed Inc (ASX: RMD) shares are in the red so far in 2025. After slipping from 52-week highs of $40.50 in January, shares in the respiratory device company currently fetch $35.71 apiece.

ResMed's fifth annual Global Sleep Survey highlights a significant global sleep crisis, revealing that 71% of employed individuals have called in sick at least once due to poor sleep, with the ...

Resmed: It is actively progressing in the field ... GE HealthCare: The company is actively using artificial intelligence and machine learning to provide clinical decision support and highly ...